Contrast Agent for CT & Cath Lab

OptiRay^® (Ioversol)

Optiray^® is licensed in X countries worldwide with 30 years of clinical experience. It has sold over X doses sold worldwide indicating high levels of trust in the brand.

OptiRay^®

• Low Osmolality (LOCM)*

• Low Viscosity*

• 4 concentrations available*

• 1 Benzene Ring (monomer)*

• 3 Iodine Atoms (tri-iodinated)*

• 6 evenly distribute Hydroxyl (OH) groups*

• Very High Hydrophilicity*

_{*Hydrophilicity and crossing cell membrane and balanaced molecule
Wible Jr. et al. European Journal of Radiology, 1995, 19, 206-211}
_{Lin Y. Med Drug J., 1992, 28,1179-1190}

_{*Osmolality and viscosity}

_{[1] Reed M et al. JACC Cardiovasc Interv. 2009;2(7):645-54. Epub 2009/07/25.}
_{[2] Kushner FG, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2009;54(23):2205-41. Epub 2009/11/28.}

_{Dawson P. et al. Text Book of Contrast Media. Oxford: Isis Medical Media Ltd, 1999.}

_{Ueda J, et al,. Acta Radiol 1992;33:596–599.}

_{Ueda J,et al. Acta Radiol 1993;34:83–87.}

_{Ueda J, et al. Acta Radiol 1997;38: 1079–1082.}

_{Lancelot E, et al. J Appl Toxicol 1999;19:341–346.}

_{Lancelot E, et al. Invest Radiol 2002;37:368–375.}

_{Seeligar E, et al. J Am Soc Nephrol 2007, 18, 2912-20.}

Contrast Induced Nephropathy (CIN) is a well-documented concern in CT. Factors leading to CIN are high viscosity, high osmolality, low hydrophilicity. Optiray has low viscosity, low osmolality and high hydrophilicity meaning that it will have greater difficulty crossing the cell membrane to cause neural toxicity. It is a balanced molecule structure^1,2.